Cargando…

Application of the “risk of ambulatory disability” (RoAD) score in a “real‐world” single‐center multiple sclerosis cohort

Survival analysis of reaching EDSS ≥4.0 based on RoAD score ≥4 (dashed line) and <4 (solid line) by Cox regression analysis. (A) Unadjusted regression analysis. (B) Regression controlled for sex and immunotherapy groups, and the trajectory of treatment changes during follow‐up.[Image: see text]...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pistor, Maximilian, Hammer, Helly, Salmen, Anke, Hoepner, Robert, Friedli, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981428/ https://www.ncbi.nlm.nih.gov/pubmed/35060326 http://dx.doi.org/10.1111/cns.13806

Ejemplares similares

Socioeconomic and Regional Disparities in Industry-Sponsored Clinical Trials in Multiple Sclerosis
por: Marti, Stefanie, et al.
Publicado: (2023)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
por: Hammer, Helly, et al.
Publicado: (2022)

Reliable brain morphometry from contrast‐enhanced T1w‐MRI in patients with multiple sclerosis
por: Rebsamen, Michael, et al.
Publicado: (2022)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2022)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
por: Friedli, Christoph, et al.
Publicado: (2021)

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?
por: Hoepner, Robert, et al.
Publicado: (2022)

Multidimensional phenotyping of the post‐COVID‐19 syndrome: A Swiss survey study
por: Diem, Lara, et al.
Publicado: (2022)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
por: Chaloulos-Iakovidis, Panagiotis, et al.
Publicado: (2021)

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
por: Pistor, Maximilian, et al.
Publicado: (2021)

Multiple sclerosis as a model to investigate SARS‐CoV‐2 effect on brain atrophy
por: Rebsamen, Michael, et al.
Publicado: (2022)

Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity
por: Miclea, Andrei, et al.
Publicado: (2017)

Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
por: Diem, Lara, et al.
Publicado: (2022)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
por: Bagnoud, Maud, et al.
Publicado: (2020)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis
por: Thiele née Schrewe, Lisa, et al.
Publicado: (2020)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
por: Diem, Lara, et al.
Publicado: (2020)

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
por: Salmen, Anke, et al.
Publicado: (2023)

Vitamin D increases glucocorticoid efficacy via inhibition of mTORC1 in experimental models of multiple sclerosis
por: Hoepner, Robert, et al.
Publicado: (2019)

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course
por: Zoehner, Greta, et al.
Publicado: (2019)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
por: Gili-Kovács, Judit, et al.
Publicado: (2021)

The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing
por: Chiavi, Deborah, et al.
Publicado: (2022)

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
por: Miclea, Andrei, et al.
Publicado: (2019)

Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
por: Nave, Stephane, et al.
Publicado: (2017)

Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis
por: Gkoutzourelas, Athanasios, et al.
Publicado: (2018)

Sexual Satisfaction in Fully Ambulatory People with Multiple Sclerosis: Does Disability Matter?
por: Dobrakowski, Pawel, et al.
Publicado: (2020)

1,25-OH(2) vitamin D(3) and AKT-inhibition increase glucocorticoid induced apoptosis in a model of T-cell acute lymphoblastic leukemia (ALL)
por: Pistor, Maximilian, et al.
Publicado: (2018)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

The added value of spinal cord lesions to disability accrual in multiple sclerosis
por: Ruggieri, Serena, et al.
Publicado: (2023)

From ZeRO to HeRO: Saving lives one HeRO at a time
por: Ratcliff, Dr. Charlotte, et al.
Publicado: (2016)

Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis
por: Hudson, Marie, et al.
Publicado: (2012)

A special road to AdS vacua
por: Cassani, Davide, et al.
Publicado: (2009)

Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort
por: Veselaj, Krenar, et al.
Publicado: (2020)

Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis
por: Lam, KH, et al.
Publicado: (2020)

Age‐dependent variation of female preponderance across different phenotypes of multiple sclerosis: A retrospective cross‐sectional study
por: Miclea, Andrei, et al.
Publicado: (2018)

Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis
por: Parker, Jennifer C, et al.
Publicado: (2009)

Socioeconomic position and health status of people who live near busy roads: the Rome Longitudinal Study (RoLS)
por: Cesaroni, Giulia, et al.
Publicado: (2010)

Roles of Sulfites in Reverse Osmosis (RO) Plants and Adverse Effects in RO Operation
por: Maeda, Yasushi
Publicado: (2022)

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling
por: Bagnoud, Maud, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mo8enujap0fomt10jtnsu7qj4d